Data on PDE9 inhibition in HF mixed; more research planned
PHOENIX — Tovinontrine increased plasma cyclic guanosine monophosphate levels in patients with HF with reduced or preserved ejection fraction but did not change N-terminal pro-B-type natriuretic peptide levels, a speaker reported.
A post hoc analysis of data indicated a possible inverse dose response relationship with lower-dose tovinontrine (Cardurion Pharmaceuticals) causing less plasma cyclic guanosine monophosphate elevation and greater reduction in NT-proBNP, according to research presented at the Heart Failure Society of America Annual Scientific Meeting.
James E. Udelson, MD, chief of